In one paragraphArticle in Journal of Alzheimer's disease : JAD, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
18 authors.
Melissa J ArmstrongDepartment of Neurology, University of Florida College of Medicine, Gainesville, FL, USA.ORCID 0000-0002-2163-1907 Easton WollneyDepartment of Health Outcomes and Biomedical Informatics, University of Florida College of Medicine, Gainesville, FL, USA.
Zhigang LiDepartment of Biostatistics, University of Florida College of Medicine, Gainesville, FL, USA.
Yunfeng DaiDepartment of Biostatistics, University of Florida College of Medicine, Gainesville, FL, USA.ORCID 0000-0003-3961-4766 Brian LaBarreDepartment of Biostatistics, University of Florida College of Medicine, Gainesville, FL, USA.ORCID 0009-0001-6566-6861 Tingchang WangDepartment of Biostatistics, University of Florida College of Medicine, Gainesville, FL, USA.ORCID 0000-0002-2377-9606 Kaitlin SovichDepartment of Neurology, University of Florida College of Medicine, Gainesville, FL, USA.
Hannah F JuryDepartment of Neurology, University of Florida College of Medicine, Gainesville, FL, USA.ORCID 0000-0001-9428-4443 James E GalvinDepartment of Neurology, Comprehensive Center for Brain Health, University of Miami Miller School of Medicine, Miami, FL, USA.
Adolfo M HenriquezDepartment of Neurology, Comprehensive Center for Brain Health, University of Miami Miller School of Medicine, Miami, FL, USA.ORCID 0000-0002-0584-5198 Henry L PaulsonDepartment of Neurology, University of Michigan, Ann Arbor, MI, USA.
Julie A FieldsDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.
Carol ManningDepartment of Neurology, University of Virginia, Charlottesville, VA, USA.
Angela S TaylorLewy Body Dementia Association, Lilburn, GA, USA.
Zachary G BakerEdson College of Nursing and Health Innovation, Arizona State University, Phoenix, AZ, USA.ORCID 0000-0001-5345-7643 Funding
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI Pamela J McLean · 2019 to 2026
$33.5MSocial Determinants of Health, Race/Ethnicity, and White Matter HyperintensitiesP30AG066506 · NIA · UNIVERSITY OF FLORIDA · PI Rosie E Curiel Cid · 2020 to 2026
$25.6MLongitudinal Imaging Biomarkers of Prodromal DLBU01NS100620 · NINDS · MAYO CLINIC ROCHESTER · PI Bradley F Boeve, KEJAL KANTARCI · 2017 to 2026
$19.2MMulticultural Community Dementia ScreeningR01AG071514 · NIA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI GALVIN, JAMES E · 2021 to 2025
$13.8MChanging the Trajectory of Mild Cognitive Impairment with CPAP Treatment of Obstructive Sleep ApneaR01AG054435 · NIA · UNIVERSITY OF PENNSYLVANIA · PI GOONERATNE, NALAKA S, WOLK, DAVID A · 2017 to 2020
$10.3MMichigan Alzheimer's Disease Core CenterP30AG053760 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ALBIN, ROGER L · 2016 to 2020
$10.1MReducing Disparities in Dementia and VCID Outcomes in a Multicultural Rural PopulationR01NS101483 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI GALVIN, JAMES E · 2019 to 2023
$8.0MThe LUCINDA TrialR01AG057681 · NIA · WEILL MEDICAL COLL OF CORNELL UNIV · PI ATWOOD, CRAIG S, BUTLER, TRACY A. · 2018 to 2024
$7.2MThe effects of Alzheimer's disease risk genes on metabolism and signaling across cell typesRF1AG075901 · NIA · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI FRAENKEL, ERNEST, TSAI, LI-HUEI · 2022 to 2025
$6.5MIND enabling CMC/safety/toxicology studies, submission of IND and pilot Phase 1 clinical trial with PV-1950R vaccine for Lewy Body Dementia (LBD)U01AG084528 · NIA · INSTITUTE FOR MOLECULAR MEDICINE · PI Michael G Agadjanyan, James E Galvin · 2024 to 2026
$5.4MDigital Detection of Dementia Studies (D cubed Studies).R01AG069765 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI BEN-MILED, ZINA, BOUSTANI, MALAZ · 2020 to 2024
$4.9MRes-Ed-ComponentP30AG059295 · NIA · WASHINGTON STATE UNIVERSITY · PI GALVIN, JAMES E, JOHANSSON, PATRIK LENNART · 2018 to 2024
$4.1MNIA NIH HHS P30 AG053760NIA NIH HHS P30 AG059295NIA NIH HHS P30 AG062677NIA NIH HHS P30 AG066506NIA NIH HHS R00 AG073463NIA NIH HHS R01 AG054435NIA NIH HHS R01 AG057681NIA NIH HHS R01 AG068128NIA NIH HHS R01 AG069765NIA NIH HHS R01 AG071514NIA NIH HHS R43 AG065088NIA NIH HHS R44 AG062072NIA NIH HHS R56 AG074889NIA NIH HHS RF1 AG075901NIA NIH HHS SB1 AG037357NIA NIH HHS T32 AG081170NIA NIH HHS U01 AG084528NINDS NIH HHS R01 NS101483NINDS NIH HHS R01 NS121099NINDS NIH HHS U01 NS100620
6 · The paper itselfAbstract
BackgroundDementia with Lewy bodies (DLB) is a common degenerative dementia, but no studies investigate bereaved caregiver experiences.ObjectiveTo investigate the experiences of caregivers three months after the death of persons with DLB using a mixed-methods approach.MethodsDyads of individuals with moderate-advanced DLB and their primary informal caregivers were followed prospectively every 6 months until the person with DLB died. Caregivers completed a study visit with questionnaires and a semi-structured interview ∼3 months later. Spearman correlation coefficients and Wilcoxon rank-sum tests evaluated the relationships of post-death measures with pre-death patient and caregiver variables. Thematic analysis was used to analyze the interviews.ResultsSeventy-three caregivers completed visits (mean 3.5 months post-death). Most of the caregivers were women (82.2%) and spouses (76.7%) or adult children (17.8%). Over 40% had scores indicating risk for clinical depression. Post-death caregiver experiences (depression, quality of life, grief, resilience) correlated with pre-death caregiver experiences. Post-death experiences did not associate with patient characteristics, disease-related symptoms, or healthcare services used in the last 6 months of life. Trajectories for caregiver measures from pre- to post-death visits varied widely. Interview themes included grief and sadness, anger, guilt and regret, relief, appreciation/gratitude, and adjusting to a new normal.ConclusionsThe finding that pre-death caregiving experiences have the strongest association with post-death experiences emphasizes the critical importance of accessible and evidence-based caregiver support before and after the death of a person with DLB. Research is needed to develop interventions for current and bereaved caregivers of individuals with DLB.Trial registration informationNCT04829656 (submitted 2021-03-22).
Indexed as
BereavementCaregiversEmotionsGriefLewy Body DiseaseAgedDeathDepressionFemaleHumansMaleMiddle AgedProspective StudiesQualitative ResearchQuality of LifeSpousesAlzheimer's diseasecaregiversdeathdementiagriefLewy body disease
Identifiers
PMID40808538
PMCPMC12412333
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390